Biologicals in der Gastroenterologie am Beispiel der Anti-TNF-Antikörper

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Deutsche Medizinische Wochenschrift

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-0030-1267508PMID 21046532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adalimumab for the treatment of fistulas in patients with Crohn's disease.

  2011cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.

  2010cited by this paper
• Adverse effects of biologics used for treating IBD.

  2010cited by this paper
• The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies

  2010cited by this paper
• Adalimumab for the treatment of fistulas in patients with Crohn’s disease

  2009cited by this paper
• Adalimumab safety in global clinical trials of patients with Crohn's disease

  2009cited by this paper
• Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

  2009cited by this paper
• Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

  2009cited by this paper
• Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

  2008cited by this paper
• A review of infliximab use in ulcerative colitis.

  2008cited by this paper
• M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial

  2008cited by this paper
• W1132 A 3-Week Course of 80 Mg Weekly Administered Adalimumab As a Rescue Therapy for Patients with Crohn's Disease Who Lost Response to 40 Mg Weekly: Relationship with Adalimumab Trough Serum Levels

  2008cited by this paper
• A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease

  2008cited by this paper
• Adalimumab in Crohn’s disease

  2007cited by this paper
• Adalimumab: in Crohn's disease.

  2007cited by this paper
• The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease

  2007cited by this paper
• Hepatitis B and C virus infections and anti‐tumor necrosis factor‐α therapy: Guidelines for clinical approach

  2006cited by this paper
• Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.

  2006cited by this paper
• Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

  2006cited by this paper
• Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

  2005cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

  2004cited by this paper
• Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

  2001cited by this paper
• Review article: efficacy of infliximab in Crohn’s disease — induction and maintenance of remission

  1999cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner

  2014cites this paper